Abstract
Topotecan is a chemotherapeutic agent that is active in the treatment of small cell lung cancer (SCLC). As a first-line agent in chemotherapy-naive patients with extensive disease SCLC, topotecan has a 39% response rate. As a second-line drug in SCLC patients with 'sensitive' disease and 'refractory' disease, the response rate is greater than 38% and less than 10%, respectively. The combination of topotecan and paclitaxel exhibits a promising overall response rate of 92% in chemotherapy-naive patients with extensive disease SCLC. Further studies are warranted with topotecan used in combination with other agents, including radiation therapy in patients with SCLC.
Original language | English (US) |
---|---|
Pages (from-to) | 11-14 |
Number of pages | 4 |
Journal | Oncologist |
Volume | 3 |
Issue number | 1 |
DOIs | |
State | Published - 1998 |
Keywords
- Extensive disease
- Limited disease
- Refractory disease
- Sensitive disease
- Small cell lung cancer
- Topotecan
ASJC Scopus subject areas
- Oncology
- Cancer Research